Matching articles for "Ryaltris"
Treatment of Allergic Rhinitis and Allergic Conjunctivitis
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2025 Mar 31; 67(1725):49-56 doi:10.58347/tml.2025.1725a
Initial treatment of allergic rhinitis (AR) depends on the severity of symptoms and whether they are intermittent or persistent (see Table 1).
Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis (online only)
View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis
Med Lett Drugs Ther. 2025 Mar 31; 67(1725):e58-63 doi:10.58347/tml.2025.1725c
View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis
Olopatadine/Mometasone (Ryaltris) for Allergic Rhinitis
The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H 1 -antihistamine olopatadine hydrochloride ( Patanase , and generics) and the corticosteroid mometasone furoate (…
Med Lett Drugs Ther. 2023 Jan 23; 65(1668):12-4 doi:10.58347/tml.2023.1668c
The FDA has approved Ryaltris (Hikma), a fixed-dose combination nasal spray containing the H 1 -antihistamine olopatadine hydrochloride ( Patanase , and generics) and the corticosteroid mometasone furoate ( Nasonex 24 HR Allergy , and generics), for treatment of seasonal allergic rhinitis symptoms in persons ≥12 years old. Ryaltris is the second intranasal antihistamine/corticosteroid combination to be approved for this indication; azelastine 0.1%/fluticasone propionate ( Dymista , and generics), which is approved for use in persons ≥6 years old, was the first. Both products are available only by prescription.
